142 related articles for article (PubMed ID: 17150037)
21. Pharmacology of Src family kinases and therapeutic implications of their modulators.
Kumar A; Jaggi AS; Singh N
Fundam Clin Pharmacol; 2015 Apr; 29(2):115-30. PubMed ID: 25545125
[TBL] [Abstract][Full Text] [Related]
22. Targeting Src in breast cancer.
Finn RS
Ann Oncol; 2008 Aug; 19(8):1379-1386. PubMed ID: 18487549
[TBL] [Abstract][Full Text] [Related]
23. SRC signaling is crucial in the growth of synovial sarcoma cells.
Michels S; Trautmann M; Sievers E; Kindler D; Huss S; Renner M; Friedrichs N; Kirfel J; Steiner S; Endl E; Wurst P; Heukamp L; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
Cancer Res; 2013 Apr; 73(8):2518-28. PubMed ID: 23580575
[TBL] [Abstract][Full Text] [Related]
24. Human melanoma cells express FGFR/Src/Rho signaling that entails an adhesion-independent caveolin-1 membrane association.
Fecchi K; Travaglione S; Spadaro F; Quattrini A; Parolini I; Piccaro G; Raggi C; Fabbri A; Felicetti F; Carè A; Fiorentini C; Sargiacomo M
Int J Cancer; 2012 Mar; 130(6):1273-83. PubMed ID: 21445970
[TBL] [Abstract][Full Text] [Related]
25. Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies.
Winiarska M; Bojarczuk K; Pyrzynska B; Bil J; Siernicka M; Dwojak M; Bobrowicz M; Miazek N; Zapala P; Zagozdzon A; Krol M; Syta A; Podszywalow-Bartnicka P; Pilch Z; Dabrowska-Iwanicka A; Juszczynski P; Efremov DG; Slabicki M; Zenz T; Le Roy A; Olive D; Rygiel TP; Leusen JH; Golab J
MAbs; 2014; 6(5):1300-13. PubMed ID: 25517315
[TBL] [Abstract][Full Text] [Related]
26. Targeting the yin and the yang: combined inhibition of the tyrosine kinase c-Src and the tyrosine phosphatase SHP-2 disrupts pancreatic cancer signaling and biology in vitro and tumor formation in vivo.
Gomes EG; Connelly SF; Summy JM
Pancreas; 2013 Jul; 42(5):795-806. PubMed ID: 23271399
[TBL] [Abstract][Full Text] [Related]
27. Involvement of Src family kinases in N-cadherin phosphorylation and beta-catenin dissociation during transendothelial migration of melanoma cells.
Qi J; Wang J; Romanyuk O; Siu CH
Mol Biol Cell; 2006 Mar; 17(3):1261-72. PubMed ID: 16371504
[TBL] [Abstract][Full Text] [Related]
28. c-CBL regulates melanoma proliferation, migration, invasion and the FAK-SRC-GRB2 nexus.
Nihal M; Wood GS
Oncotarget; 2016 Aug; 7(33):53869-53880. PubMed ID: 27472394
[TBL] [Abstract][Full Text] [Related]
29. Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: a rationale to combine targeted drugs based on protein expression inhibition profiles.
Aftimos PG; Wiedig M; Langouo Fontsa M; Awada A; Ghanem G; Journe F
Int J Oncol; 2013 Sep; 43(3):919-26. PubMed ID: 23835698
[TBL] [Abstract][Full Text] [Related]
30. FAK regulates E-cadherin expression via p-SrcY416/p-ERK1/2/p-Stat3Y705 and PPARγ/miR-125b/Stat3 signaling pathway in B16F10 melanoma cells.
Pei G; Lan Y; Chen D; Ji L; Hua ZC
Oncotarget; 2017 Feb; 8(8):13898-13908. PubMed ID: 28108732
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo.
Hingorani P; Zhang W; Gorlick R; Kolb EA
Clin Cancer Res; 2009 May; 15(10):3416-22. PubMed ID: 19447875
[TBL] [Abstract][Full Text] [Related]
32. Synthetic SRC-kinase domain inhibitors and their structural requirements.
Schenone S; Manetti F; Botta M
Anticancer Agents Med Chem; 2007 Nov; 7(6):660-80. PubMed ID: 18045061
[TBL] [Abstract][Full Text] [Related]
33. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells.
Nam S; Kim D; Cheng JQ; Zhang S; Lee JH; Buettner R; Mirosevich J; Lee FY; Jove R
Cancer Res; 2005 Oct; 65(20):9185-9. PubMed ID: 16230377
[TBL] [Abstract][Full Text] [Related]
34. SRC family kinases as potential therapeutic targets for malignancies and immunological disorders.
Benati D; Baldari CT
Curr Med Chem; 2008; 15(12):1154-65. PubMed ID: 18473810
[TBL] [Abstract][Full Text] [Related]
35. RaLP, a new member of the Src homology and collagen family, regulates cell migration and tumor growth of metastatic melanomas.
Fagiani E; Giardina G; Luzi L; Cesaroni M; Quarto M; Capra M; Germano G; Bono M; Capillo M; Pelicci P; Lanfrancone L
Cancer Res; 2007 Apr; 67(7):3064-73. PubMed ID: 17409413
[TBL] [Abstract][Full Text] [Related]
36. Src inhibitors in breast cancer therapy.
Hiscox S; Nicholson RI
Expert Opin Ther Targets; 2008 Jun; 12(6):757-67. PubMed ID: 18479222
[TBL] [Abstract][Full Text] [Related]
37. Targeting Src family kinases in anti-cancer therapies: turning promise into triumph.
Zhang S; Yu D
Trends Pharmacol Sci; 2012 Mar; 33(3):122-8. PubMed ID: 22153719
[TBL] [Abstract][Full Text] [Related]
38. Augmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity.
Teng Y; Cai Y; Pi W; Gao L; Shay C
J Hematol Oncol; 2017 Jun; 10(1):118. PubMed ID: 28606127
[TBL] [Abstract][Full Text] [Related]
39. SRC kinase inhibitors: an update on patented compounds.
Schenone S; Brullo C; Musumeci F; Radi M; Castagnolo D
Curr Med Chem; 2011; 18(33):5061-78. PubMed ID: 22050754
[TBL] [Abstract][Full Text] [Related]
40. An anti-Ras cancer potential of PP1, an inhibitor specific for Src family kinases: in vitro and in vivo studies.
He H; Hirokawa Y; Levitzki A; Maruta H
Cancer J; 2000; 6(4):243-8. PubMed ID: 11038144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
